B+
Bull case
25%
Probability
Target price
$8.50
+56.0% vs current
IMA
ImageneBioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$5.00
-8.3% vs current
B-
Bear case
30%
Probability
Target price
$2.80
-48.6% vs current
AI sentiment snapshot
Latest data as of 2026-04-18
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+42.7
Score
AI commentary
Cautious monitoring view. Primary-source support is solid, but the evidence set is still mostly filing and company-update based rather than data-rich. The deterministic prior is negative, evidence quality is only middling, and catalyst density is low. Net: financing and runway improve survivability, but the stock likely needs materially better clinical visibility before it deserves a more constructive stance.
RankAlpha Sentiment Codex - 2026-04-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-14catalystApril 2026 financing reduces near-term balance-sheet pressure but adds dilutionHigh impact
Imagene announced a $30 million private placement of pre-funded warrants at $5.199 per warrant, expected to fund further IMG-007 work in alopecia areata and late-stage atopic dermatitis activities [#8-K-2026-04-13]. This is supportive for continuity of development, but the stock is likely to keep discounting dilution until the new capital converts into cleaner clinical visibility.
2026-07-17eventADAPTIVE Phase 2b topline remains the core value inflectionHigh impact
Management said the Phase 2b ADAPTIVE study in moderate-to-severe atopic dermatitis is meeting enrollment expectations and remains on track for a topline readout in 2027, while the protocol amendment is intended to broaden dose/exposure characterization [#PR-2026-03-10]. With IMG-007 as the only clinical asset in development, this remains the main upside driver but timing is still broad rather than near-dated.
2027-03-10catalystRunway support extends the monitoring window for IMG-007 executionHigh impact
The 10-K reported $135.3 million of cash, cash equivalents and marketable securities at December 31, 2025 and said existing resources were sufficient for at least 12 months from the filing date [#10-K-2026-03-10]. Combined with the announced April financing, the company appears funded long enough to keep ADAPTIVE and alopecia areata development moving, but the thesis still needs data rather than just cash.
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-18 • Updated nightlySource: Internal modelMethodology